2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106019B
    Liarozole fumarate 145858-52-2 98%
    Liarozole fumarate, an imidazole derivative, is a potent inhibitor of cytochrome P450-dependent all-trans retinoic acid 4-hydroxylase and acts by increasing the levels of all-trans retinoic acid in plasma and skin.
    Liarozole fumarate
  • HY-106181A
    Rivoglitazone hydrochloride 299176-11-7 98%
    Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes.
    Rivoglitazone hydrochloride
  • HY-106203B
    (R)-Crinecerfont 2649012-21-3 98%
    (R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (R)-Crinecerfont
  • HY-106203C
    Crinecerfont tosylate 2649012-17-7 98%
    Crinecerfont tosylate (SSR-125543 tosylate) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont tosylate can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont tosylate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont tosylate
  • HY-106266B
    Chiglitazar sodium 2390374-10-2 98%
    Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.
    Chiglitazar sodium
  • HY-106277A
    Fasitibant chloride hydrochloride 869880-33-1 98%
    Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis.
    Fasitibant chloride hydrochloride
  • HY-106278A
    GW 590735 sodium 343322-50-9 98%
    GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735.
    GW 590735 sodium
  • HY-106577A
    (-)-(S)-Cibenzoline 103419-18-7 98%
    (-)-(S)-Cibenzoline (Escibenzoline), a S(+)-enantiomer of Cibenzoline, is an antiarrhythmic agent.
    (-)-(S)-Cibenzoline
  • HY-106818A
    Monatepil maleate 103379-03-9 98%
    Monatepil maleate (AJ-2615) is a potent and orally active Ca2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia.
    Monatepil maleate
  • HY-106833A
    SDZ-62-434 115621-95-9 98%
    SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies.
    SDZ-62-434
  • HY-107176A
    Hyzetimibe 1266548-74-6 98%
    Hyzetimibe is a cholesterol absorption inhibitor. Hyzetimibe blocks the intestinal absorption of cholesterol and phytol. Hyzetimibe is well tolerated in animal models, with an LDmax 2000 mg/kg in rats and an LDmax 500 mg/kg in rhesus monkeys.
    Hyzetimibe
  • HY-107343R
    Docosahexaenoic acid ethyl ester (Standard) 81926-94-5
    Docosahexaenoic acid ethyl ester (Standard) is the analytical standard of Docosahexaenoic acid ethyl ester. This product is intended for research and analytical applications. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects.
    Docosahexaenoic acid ethyl ester (Standard)
  • HY-107542R
    Oleoylethanolamide (Standard) 111-58-0
    Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
    Oleoylethanolamide (Standard)
  • HY-107723A
    CGP71683 192321-23-6 98%
    CGP 71683 Free base serves as a powerful and highly selective non-peptide antagonist targeting the NPY Y(5) receptor, making it a valuable tool in obesity research.
    CGP71683
  • HY-107725A
    BIBO3304 diTFA 2310085-85-7 98%
    BIBO3304 (diTFA) is an orally effective and selective neuropeptide Y (NPY) Y1 receptor antagonist. BIBO3304 (diTFA) has a high affinity for both human and rat Y1 receptors, with IC50 values of 0.38 and 0.72 nM, respectively. BIBO3304 (diTFA) promotes bone-tendon healing through the Wnt/β-catenin signaling pathway.
    BIBO3304 diTFA
  • HY-107830R
    Methyl cholate (Standard) 1448-36-8
    Methyl cholate (Standard) is the analytical standard of Methyl cholate. This product is intended for research and analytical applications. Methyl Cholate is methyl ester form of Cholic acid. Cholic acid is one of the major bile acids produced by the liver, where it is synthesized from cholesterol[1].
    Methyl cholate (Standard)
  • HY-108036B
    Pro-xylane 439685-79-7 ≥98.0%
    Pro-xylane (Hydroxypropyl tetrahydropyrantriol) is a bioactive C-glycoside that targets the biosynthesis pathway of glycosaminoglycans/mucopolysaccharides (GAGs) in the skin matrix and can be absorbed transdermally. Pro-xylane stimulates the biosynthesis of GAGs in fibroblasts, enhances the structural stability of the skin extracellular matrix, improves skin elasticity and moisturizing ability, and delays wrinkle formation. Pro-xylane can effectively promote the synthesis of collagen fibers and hyaluronic acid in the dermis. Pro-xylane is used in the field of anti-aging cosmetics to improve skin hydration and elasticity. Pro-xylane is eco-friendly and biodegradable.
    Pro-xylane
  • HY-108694R
    γ-Tocotrienol (Standard) 14101-61-2
    γ-Tocotrienol (Standard) is the analytical standard of γ-Tocotrienol. This product is intended for research and analytical applications. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment.
    γ-Tocotrienol (Standard)
  • HY-109018A
    Velagliflozin proline 1539295-26-5 99.43%
    Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
    Velagliflozin proline
  • HY-109018B
    Velagliflozin proline hydrate 1661838-94-3 99.43%
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
    Velagliflozin proline hydrate
Cat. No. Product Name / Synonyms Application Reactivity